67-68-5 | Dimethyl sulfoxide (DMSO)

Chemical type

• Polar aprotic solvent
• Organosulfur compound

^[1]

• Organic solvent

^[2]

• Polar aprotic solvent

^[3]

Key properties

• Common laboratory solvent
• Cryoprotectant
• Penetration enhancer

^[1]

• Used at 1% concentration as vehicle
• Dissolves PD98059 for intraperitoneal injection
• No therapeutic effect alone (serves as control vehicle)
• Commonly used in pharmacological studies for drug delivery

^[2]

• Penetrates biological membranes readily
• Hygroscopic
• Miscible with water and most organic solvents

^[3]

• Used as a vehicle/control solvent in cell culture drug validation experiments in the study (e.g., for bexarotene treatment)

^[1]

• Vehicle for administering PD98059 in EAE treatment
• Control substance in experimental groups
• Solvent in biochemical and molecular assays

^[2]

• Cryoprotectant for cell freezing (inferred)
• Solvent for water-insoluble substances in biological assays (inferred)

^[3]

Classification by use

• Laboratory solvents
• Chemical reagents

^[1]

• Chemicals used as solvents
• Chemicals used in drug delivery vehicles
• Chemicals used in pharmacological experiments

^[2]

• Chemicals used in cell preservation

^[3]

A trustworthy factory and manufacturer

Demei Chemical Technology Co., Ltd. is a modern high-tech enterprise integrating R&D, production, and sales. The company's founder, Dr. Arron, born in April 1975, graduated from the School of Mechanical Engineering at Yanshan University and has been engaged in research in the fields of mechanical engineering and chemical synthesis for many years. The company's products focus on the chemical industry, primarily dealing in chemical raw materials and chemical production machinery and equipment. With its strong technical capabilities, advanced production equipment, and strict quality management system, the company has earned the trust of customers worldwide.

1. [Cite:1] Anoikis- and m6A-related lncRNA analysis to identify prognostic indicators in liver hepatocellular carcinoma, Electronic Journal of Biotechnology, Volume 79, January 2026, 100701
2. [Cite:2] Mitogen-activated protein kinase inhibitor PD98059 improves neuroimmune dysfunction in experimental autoimmune encephalomyelitis in SJL/J mice through the inhibition of nuclear factor-kappa B signaling in B cells, Brain Research Bulletin, Volume 194, March 2023, Pages 45-53
3. [Cite:3] Penicillin–Streptomycin Treatment Rewires Core Metabolic and Ribosomal Programs in HepG2 Cells, J. Proteome Res. 2026, 25, 2, 1082–1094